invIOs GmbH
PrivateLast Round
Series A
Oct 15, 2024
Total Funding Raised
$8.94M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
invIOs GmbH operates in Healthcare & Life Sciences and is based in Vienna. Its latest recorded funding round was a Series A round in October 2024.
invIOs GmbH is a biotechnology company that develops next-generation cancer immunotherapies using its proprietary EPiC cell therapy platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Data as a Service, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
invIOs GmbH Comparables
Compare invIOs GmbH with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| HotSpot Therapeutics | 68% | |
| Adaptimmune Therapeutics | 68% | |
| Nurix Therapeutics, Inc. | 68% |
For institutional investors. Book with your work email.
invIOs GmbH Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
invIOs GmbH Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ligand Pharmaceuticals | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 315% MoM.
- Jul 25, 2026
Monthly visitors increased 1667% MoM, from 36 to 636.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withOct 15, 2026
invIOs GmbH partners with Dana-Farber Cancer Institute, Inc. to jointly develop treatments against glioblastoma.
For institutional investors. Book with your work email.
invIOs GmbH Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about invIOs GmbH's valuation, stock price, and market status.
Is invIOs GmbH a public or private company?
invIOs GmbH is a private company.
What is the current stock price of invIOs GmbH?
invIOs GmbH is a private company, so its shares have no public market price. Caplight tracks invIOs GmbH's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is invIOs GmbH worth (valuation)?
Valuation information for invIOs GmbH is not publicly available.
Can I buy invIOs GmbH stock?
invIOs GmbH shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was invIOs GmbH's last funding round?
invIOs GmbH's most recent funding round was Series A on October 15, 2024.
Who are the main investors in invIOs GmbH?
Key investors in invIOs GmbH include Ligand Pharmaceuticals.
Will invIOs GmbH IPO soon?
No public IPO plans have been announced for invIOs GmbH.
How can I track invIOs GmbH secondary market activity?
Caplight tracks bids, offers, and trades in invIOs GmbH's shares on secondary markets.